What are the side effects of Necitumumab?

Necitumumabis a humanizedIgG1 anti-EGFR. In the phase III SQUIRE trial, nesituzumab in combination with cisplatin and gemcitabine as first-line treatment showed a reduced risk of death and higher disease control rates in advanced squamous non-small cell lung cancer. Nexituzumab is now a new first-line treatment option for squamous non-small cell lung cancer,and further biomarker studies are needed to improve patient selection.

The most common adverse reactions (all grades) observed in patients treated with nestuzumab were ≥15% and ≥2% more frequent than gemcitabine and cisplatin alone, respectively, and included rash, vomiting, diarrhea, and acneiform dermatitis. The most common serious adverse events that occurred in ≥2% of patients treated with nesituzumab compared with patients who received gemcitabine and cisplatin alone were venous thromboembolic events (including pulmonary embolism), rash, and vomiting. Hypomagnesemia was the most common electrolyte abnormality in patients who received cistuzumab in combination with gemcitabine and cisplatin, and 12% of patients discontinued cistuzumab treatment due to adverse reactions. The most common toxicity was rash.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.